Miltenyi Biotec, Inc.
🇺🇸United States
Stem Cell Implantation in Patients Undergoing CABG
Phase 1
Terminated
- Conditions
- Ischemic CardiomyopathyCoronary Artery Disease
- Interventions
- Device: Autologous CD133+ Bone Marrow Stem CellsOther: Carrier Solution
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Miltenyi Biotec, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01721902
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath